08 October 2018
An extensive range of products for companion animals, equine and food producing animals will be added to the Dechra Veterinary Products portfolio throughout the next twelve months.
Dechra Veterinary Products will commence the roll out later this summer following its acquisition of Netherlands-based AST Farma and Le Vet in February of this year.
There will be new additions to Dechra’s antibiotic range, such as Doxybactin® and Spizobactin® that support the effective and responsible use of antibiotics and feature innovative SmartTab® Technology.
Dechra’s dermatology portfolio will be further strengthened with new products including Dermanolon® alongside its well-known existing brands Canaural® and Malaseb®.
New anaesthesia and analgesia options beginning with the launch of Tralieve®, the first veterinary licenced tramadol available in tablet and injectable preparations, will complement Dechra’s existing products, offering veterinary professionals even more pain management solutions for patients.
In addition to new launches, Le Vet products that were previously marketed by other pharmaceutical companies in the UK will be relaunched under Dechra’s own branding, giving vets continued access to the same great products, backed by Dechra’s high level of technical support.
Mark Floyd, Dechra’s Country Manager UK and Ireland, said: “Our commitment has always been to offer a wide choice of high quality, competitively priced products that provide vets with a range of options in their day to day practice.
“We are very excited to be marketing these products in the UK and to be able to bring a number of popular Le Vet treatments under our own banner.”
The new therapies will be available through veterinary wholesalers in the coming months. To be the first to hear details on the expanded Dechra range of products for companion animals, equine and food producing animals, register below for more information.
Extensive portfolio expansion for Dechra Veterinary Products